You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Express Scripts
McKinsey
Boehringer Ingelheim
AstraZeneca

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04043806 A Study Evaluating the Long-term Safety of VX-445 Combination Therapy Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2019-08-01 This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA).
NCT04058353 A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2019-08-01 This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).
NCT04058366 Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2019-11-01 This study will evaluate the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).
NCT04105972 A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2019-09-01 This study will evaluate the efficacy, safety, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for F508del.
NCT04183790 Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2020-02-01 This study will evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF).
NCT04353817 A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2020-06-01 This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).
NCT04362761 A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy Not yet recruiting Vertex Pharmaceuticals Incorporated Phase 3 2020-04-01 This study will evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in subjects with cystic fibrosis (CF) who are homozygous for F508del.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

Condition Name

Condition Name for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Intervention Trials
Cystic Fibrosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Intervention Trials
Fibrosis 7
Cystic Fibrosis 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

Clinical Trial Phase

Clinical Trial Phase for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Clinical Trial Phase Trials
Phase 3 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Clinical Trial Phase Trials
Not yet recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

Sponsor Name

Sponsor Name for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Sponsor Trials
Vertex Pharmaceuticals Incorporated 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor
Sponsor Trials
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
AstraZeneca
Dow
Harvard Business School
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.